Hyperglycemia, classified with multiple biomarkers simultaneously in men without diabetes, and risk of fatal prostate cancer

Michael T. Marrone, Elizabeth Selvin, John R. Barber, Elizabeth A Platz, Corinne E. Joshu

Research output: Contribution to journalArticle

Abstract

The association between hyperglycemia and prostate cancer risk is inconsistent, and its association with prostate cancer mortality is understudied. Thus, we investigated the association between hyperglycemia and prostate cancer risk and mortality using multiple biomarkers simultaneously to classify hyper- and normoglycemia. We conducted a prospective analysis of 5,162 cancer-free men attending visit 2 (1990-1992) of the Atherosclerosis Risk in Communities (ARIC) study followed for total (N ¼ 671) and lethal (N ¼ 69) prostate cancer incidence and prostate cancer mortality (N ¼ 64) through 2012. Men without diagnosed diabetes were classified as normo- or hyperglycemic using joint categories of fasting glucose, glycated hemoglobin, and glycated albumin (or fructosamine) defined by clinical or research cutpoints. We evaluated the multi-variable-adjusted association of hyperglycemia with prostate cancer incidence and mortality using Cox proportional hazards regression; men with diagnosed diabetes were included as a separate exposure category. Among 4,753 men without diagnosed diabetes, 61.5% were classified as having hyperglycemia (high on 1 biomarker). HbA1c and glycated albumin together classified 61.9% of 1,736 men with normal fasting glucose as normoglycemic. Compared with men who were normal on all three biomarkers, men who were high on 1 biomarker had an increased risk of lethal [HR, 2.50; 95% confidence interval (CI), 1.12-5.58] and fatal (HR, 3.20; 95% CI, 1.26-8.48) disease, but not total prostate cancer incidence (HR, 0.98; 95% CI, 0.81-1.20); associations were similar including fructosamine instead of glycated albumin. Our findings indicate hyperglycemia is associated with an increased risk of lethal and fatal prostate cancer, but not total prostate cancer incidence.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalCancer Prevention Research
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Hyperglycemia
Prostatic Neoplasms
Biomarkers
Fructosamine
Mortality
Incidence
Confidence Intervals
Fasting
Glucose
Glycosylated Hemoglobin A
Atherosclerosis
Joints
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{a997dabc422344aab601320152868957,
title = "Hyperglycemia, classified with multiple biomarkers simultaneously in men without diabetes, and risk of fatal prostate cancer",
abstract = "The association between hyperglycemia and prostate cancer risk is inconsistent, and its association with prostate cancer mortality is understudied. Thus, we investigated the association between hyperglycemia and prostate cancer risk and mortality using multiple biomarkers simultaneously to classify hyper- and normoglycemia. We conducted a prospective analysis of 5,162 cancer-free men attending visit 2 (1990-1992) of the Atherosclerosis Risk in Communities (ARIC) study followed for total (N ¼ 671) and lethal (N ¼ 69) prostate cancer incidence and prostate cancer mortality (N ¼ 64) through 2012. Men without diagnosed diabetes were classified as normo- or hyperglycemic using joint categories of fasting glucose, glycated hemoglobin, and glycated albumin (or fructosamine) defined by clinical or research cutpoints. We evaluated the multi-variable-adjusted association of hyperglycemia with prostate cancer incidence and mortality using Cox proportional hazards regression; men with diagnosed diabetes were included as a separate exposure category. Among 4,753 men without diagnosed diabetes, 61.5{\%} were classified as having hyperglycemia (high on 1 biomarker). HbA1c and glycated albumin together classified 61.9{\%} of 1,736 men with normal fasting glucose as normoglycemic. Compared with men who were normal on all three biomarkers, men who were high on 1 biomarker had an increased risk of lethal [HR, 2.50; 95{\%} confidence interval (CI), 1.12-5.58] and fatal (HR, 3.20; 95{\%} CI, 1.26-8.48) disease, but not total prostate cancer incidence (HR, 0.98; 95{\%} CI, 0.81-1.20); associations were similar including fructosamine instead of glycated albumin. Our findings indicate hyperglycemia is associated with an increased risk of lethal and fatal prostate cancer, but not total prostate cancer incidence.",
author = "Marrone, {Michael T.} and Elizabeth Selvin and Barber, {John R.} and Platz, {Elizabeth A} and Joshu, {Corinne E.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/1940-6207.CAPR-18-0216",
language = "English (US)",
volume = "12",
pages = "103--112",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Hyperglycemia, classified with multiple biomarkers simultaneously in men without diabetes, and risk of fatal prostate cancer

AU - Marrone, Michael T.

AU - Selvin, Elizabeth

AU - Barber, John R.

AU - Platz, Elizabeth A

AU - Joshu, Corinne E.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The association between hyperglycemia and prostate cancer risk is inconsistent, and its association with prostate cancer mortality is understudied. Thus, we investigated the association between hyperglycemia and prostate cancer risk and mortality using multiple biomarkers simultaneously to classify hyper- and normoglycemia. We conducted a prospective analysis of 5,162 cancer-free men attending visit 2 (1990-1992) of the Atherosclerosis Risk in Communities (ARIC) study followed for total (N ¼ 671) and lethal (N ¼ 69) prostate cancer incidence and prostate cancer mortality (N ¼ 64) through 2012. Men without diagnosed diabetes were classified as normo- or hyperglycemic using joint categories of fasting glucose, glycated hemoglobin, and glycated albumin (or fructosamine) defined by clinical or research cutpoints. We evaluated the multi-variable-adjusted association of hyperglycemia with prostate cancer incidence and mortality using Cox proportional hazards regression; men with diagnosed diabetes were included as a separate exposure category. Among 4,753 men without diagnosed diabetes, 61.5% were classified as having hyperglycemia (high on 1 biomarker). HbA1c and glycated albumin together classified 61.9% of 1,736 men with normal fasting glucose as normoglycemic. Compared with men who were normal on all three biomarkers, men who were high on 1 biomarker had an increased risk of lethal [HR, 2.50; 95% confidence interval (CI), 1.12-5.58] and fatal (HR, 3.20; 95% CI, 1.26-8.48) disease, but not total prostate cancer incidence (HR, 0.98; 95% CI, 0.81-1.20); associations were similar including fructosamine instead of glycated albumin. Our findings indicate hyperglycemia is associated with an increased risk of lethal and fatal prostate cancer, but not total prostate cancer incidence.

AB - The association between hyperglycemia and prostate cancer risk is inconsistent, and its association with prostate cancer mortality is understudied. Thus, we investigated the association between hyperglycemia and prostate cancer risk and mortality using multiple biomarkers simultaneously to classify hyper- and normoglycemia. We conducted a prospective analysis of 5,162 cancer-free men attending visit 2 (1990-1992) of the Atherosclerosis Risk in Communities (ARIC) study followed for total (N ¼ 671) and lethal (N ¼ 69) prostate cancer incidence and prostate cancer mortality (N ¼ 64) through 2012. Men without diagnosed diabetes were classified as normo- or hyperglycemic using joint categories of fasting glucose, glycated hemoglobin, and glycated albumin (or fructosamine) defined by clinical or research cutpoints. We evaluated the multi-variable-adjusted association of hyperglycemia with prostate cancer incidence and mortality using Cox proportional hazards regression; men with diagnosed diabetes were included as a separate exposure category. Among 4,753 men without diagnosed diabetes, 61.5% were classified as having hyperglycemia (high on 1 biomarker). HbA1c and glycated albumin together classified 61.9% of 1,736 men with normal fasting glucose as normoglycemic. Compared with men who were normal on all three biomarkers, men who were high on 1 biomarker had an increased risk of lethal [HR, 2.50; 95% confidence interval (CI), 1.12-5.58] and fatal (HR, 3.20; 95% CI, 1.26-8.48) disease, but not total prostate cancer incidence (HR, 0.98; 95% CI, 0.81-1.20); associations were similar including fructosamine instead of glycated albumin. Our findings indicate hyperglycemia is associated with an increased risk of lethal and fatal prostate cancer, but not total prostate cancer incidence.

UR - http://www.scopus.com/inward/record.url?scp=85061127651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061127651&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-18-0216

DO - 10.1158/1940-6207.CAPR-18-0216

M3 - Article

C2 - 30538098

AN - SCOPUS:85061127651

VL - 12

SP - 103

EP - 112

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -